Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy
ERBB2 amp+ mCRC is a small but clinically relevant subgroup with inferior rwPFS across current first-line treatments, highlighting the need for better strategies.
Authors
- Harlan Pittell (ORCID: https://orcid.org/0000-0001-9969-4927)
- Yoshiaki Nakamura (ORCID: https://orcid.org/0000-0002-5241-6855)
- Yuki Matsubara (ORCID: https://orcid.org/0000-0003-4009-0015)
- Toshihiro Misumi (ORCID: https://orcid.org/0000-0001-8339-2895)
- Hideaki Bando (ORCID: https://orcid.org/0000-0001-5041-2765)
- Takayuki Yoshino (ORCID: https://orcid.org/0000-0002-0489-4756)
- A. Ohtsu
- Eri Tajima (ORCID: https://orcid.org/0009-0002-2051-1548)
- Dionne Ng
Institutions
- National Cancer Center Hospital East (JP)
- Flatiron Health (United States) (US)
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1038/s41416-025-03270-4
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Flatiron Health